Double Point Ventures, Bioluminescence Ventures and Earlybird Venture Capital led a $34m funding round in GEMMA Biotherapeutics.

Double Point Ventures, Bioluminescence Ventures and Earlybird Venture Capital, investment firms, led a $34m funding round in GEMMA Biotherapeutics, a therapeutics company focused on advancing research and global access to life-changing advanced therapies, with participation from Savanne Life Sciences. "We are delighted by the enthusiastic support from our engaged and high-quality partners, who share our vision for the future of gene therapy [...] Their involvement comes at a pivotal moment in the industry, and together, we are committed to expanding and speeding access to affordable gene therapies for the patients who need them most," Jim Wilson, GEMMA Biotherapeutics President and CEO.